MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
11.04
+0.06
+0.55%
After Hours: 11.32 +0.28 +2.54% 17:11 12/05 EST
OPEN
11.02
PREV CLOSE
10.98
HIGH
11.05
LOW
10.89
VOLUME
54.03K
TURNOVER
--
52 WEEK HIGH
15.40
52 WEEK LOW
3.350
MARKET CAP
322.17M
P/E (TTM)
-4.8943
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTNM last week (1124-1128)?
Weekly Report · 4d ago
Contineum Therapeutics to Participate in Evercore Healthcare Conference
Reuters · 11/24 21:05
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
Barchart · 11/24 15:05
Contineum Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 11/24 14:54
Contineum Therapeutics Price Target Cut to $14.00/Share From $16.00 by Baird
Dow Jones · 11/24 14:54
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $14
Benzinga · 11/24 14:43
Contineum price target lowered to $14 from $16 at Baird
TipRanks · 11/24 12:35
Weekly Report: what happened at CTNM last week (1117-1121)?
Weekly Report · 11/24 10:39
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.